BSE: 524500 | NSE: KILITCH | Pharmaceuticals & Drugs | Small Cap
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Kilitch Drugs (India) Ltd is a below average quality company.
The key valuation ratios of Kilitch Drugs (India) Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Kilitch Drugs (India) Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | -0.7% | -2% | -0.3% | 6% | 13.8% | 3.8% | 4.9% | 7.8% | 9.9% | 10.8% | - |
| Value Creation Index ⓘ | -1.1 | -1.2 | -1.0 | -0.6 | 0.0 | -0.7 | -0.7 | -0.4 | -0.3 | -0.2 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 19 | 21 | 28.1 | 50.5 | 96.4 | 60.8 | 70 | 105 | 118 | 132 | 148 |
| Sales YoY Gr. | - | 10.5% | 33.9% | 79.3% | 91.1% | -37% | 15.2% | 50.2% | 12% | 11.7% | - |
| Adj EPS ⓘ | -0.1 | -1.7 | 0.3 | 3.6 | 8.5 | 1.3 | 3 | 6 | 8.9 | 9.4 | 13.7 |
| YoY Gr. | - | NA | NA | 1332% | 136.3% | -84.2% | 123.1% | 100.7% | 49% | 4.9% | - |
| BVPS (₹) ⓘ | 89.6 | 88.1 | 88.9 | 92.8 | 97.7 | 97.5 | 104.9 | 112.4 | 122.3 | 138.4 | 147.3 |
| Adj Net Profit ⓘ | -0.2 | -2.3 | 0.3 | 4.9 | 13 | 2.1 | 4.6 | 9.4 | 13.9 | 15.1 | 22 |
| Cash Flow from Ops. ⓘ | -7.6 | 18 | 0.6 | -1.3 | 7.4 | 7.3 | 6.1 | 5.2 | 6.1 | -1.2 | - |
| Debt/CF from Ops. ⓘ | 0 | 0 | 1.1 | -0.6 | 1.3 | 1.7 | 2.4 | 3.9 | 3.6 | -26.3 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 24% | 6.4% | 23.4% | 11.7% | ||||
| Adj EPS ⓘ | NA | 2.1% | 46.4% | 4.9% | ||||
| BVPSⓘ | 4.9% | 7.2% | 9.7% | 13.2% | ||||
| Share Price | 25.7% | 21.3% | 25.2% | -5.1% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | -0.1 | -1.9 | 0.3 | 3.9 | 9.2 | 1.4 | 3 | 5.5 | 7.5 | 7.2 | 9.6 |
| Op. Profit Mgn % ⓘ | -6 | -15 | 0.5 | 11.1 | 17 | 1.9 | 7.6 | 11.3 | 14.7 | 15.5 | 12.2 |
| Net Profit Mgn % ⓘ | -0.8 | -10.7 | 1.2 | 9.8 | 13.5 | 3.4 | 6.6 | 8.9 | 11.8 | 11.5 | 14.9 |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0 |
| Working Cap Days ⓘ | 725 | 536 | 280 | 193 | 173 | 373 | 364 | 299 | 314 | 319 | 152 |
| Cash Conv. Cycle ⓘ | 170 | 244 | 163 | 86 | 64 | 107 | 59 | 39 | 41 | 70 | 80 |
Return on Equity has increased versus last 3 years average to 9.60%
Sales growth is growing at healthy rate in last 3 years 23.41%
Net Profit is growing at healthy rate in last 3 years 46.39%
Sales growth is good in last 4 quarters at 11.48%
No data to display
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 13.7 | 10.2 |
| TTM Sales (₹ Cr.) | 148 | 158 |
| BVPS (₹.) ⓘ | 147.3 | 117.7 |
| Reserves (₹ Cr.) ⓘ | 221 | 173 |
| P/BV ⓘ | 2.11 | 2.64 |
| PE ⓘ | 22.70 | 30.39 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 298.45 / 469.85 |
| All Time Low / High (₹) | 0.75 / 469.85 |
| Market Cap (₹ Cr.) | 500 |
| Equity (₹ Cr.) | 16.1 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 43 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 19 | 21 | 28 | 50 | 96 | 61 | 70 | 105 | 118 | 132 |
| Operating Expenses ⓘ | 21 | 25 | 29 | 45 | 81 | 60 | 65 | 94 | 100 | 111 |
| Manufacturing Costs | 2 | 4 | 4 | 3 | 4 | 5 | 5 | 8 | 8 | 7 |
| Material Costs | 7 | 9 | 11 | 26 | 53 | 36 | 39 | 60 | 58 | 66 |
| Employee Cost | 3 | 3 | 3 | 4 | 5 | 6 | 5 | 6 | 7 | 8 |
| Other Costs ⓘ | 8 | 9 | 10 | 11 | 18 | 13 | 15 | 20 | 27 | 30 |
| Operating Profit ⓘ | -2 | -4 | -1 | 6 | 16 | 1 | 5 | 11 | 17 | 20 |
| Operating Profit Margin (%) | -8.6% | -16.9% | -2.0% | 11.1% | 16.2% | 1.9% | 7.6% | 10.6% | 14.7% | 15.5% |
| Other Income ⓘ | 3 | 3 | 2 | 3 | 6 | 6 | 4 | 5 | 5 | 6 |
| Interest ⓘ | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 |
| Depreciation ⓘ | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | -1 | -2 | 0 | 7 | 20 | 5 | 8 | 14 | 19 | 23 |
| Tax ⓘ | -1 | 0 | 0 | 1 | 5 | 1 | 1 | 3 | 4 | 6 |
| Profit After Tax | 0 | -2 | 0 | 6 | 15 | 4 | 6 | 11 | 16 | 18 |
| PAT Margin (%) | -1.0% | -9.8% | -0.1% | 12.3% | 15.3% | 7.3% | 8.8% | 10.0% | 13.3% | 13.4% |
| Adjusted EPS (₹) | -0.1 | -1.6 | 0.0 | 4.5 | 9.6 | 2.9 | 4.0 | 6.8 | 10.1 | 10.9 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 11% | 5% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 119 | 117 | 118 | 127 | 150 | 150 | 163 | 175 | 191 | 223 |
| Share Capital ⓘ | 13 | 13 | 13 | 14 | 15 | 15 | 15 | 16 | 16 | 16 |
| Reserves ⓘ | 105 | 103 | 104 | 114 | 135 | 135 | 147 | 160 | 175 | 206 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 0 | 0 | 1 | 1 | 9 | 13 | 15 | 20 | 22 | 31 |
| Long Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short Term Debt | 0 | 0 | 1 | 1 | 9 | 13 | 15 | 20 | 22 | 31 |
| Trade Payables | 2 | 4 | 6 | 8 | 5 | 8 | 14 | 28 | 29 | 26 |
| Others Liabilities ⓘ | 5 | 4 | 4 | 8 | 6 | 2 | 4 | 8 | 9 | 5 |
| Total Liabilities ⓘ | 126 | 125 | 128 | 144 | 171 | 173 | 195 | 231 | 250 | 285 |
Fixed Assets | ||||||||||
| Gross Block | 23 | 23 | 24 | 25 | 26 | 27 | 28 | 36 | 38 | 40 |
| Accumulated Depreciation | 13 | 15 | 16 | 17 | 18 | 20 | 21 | 22 | 23 | 24 |
| Net Fixed Assetsⓘ | 9 | 8 | 8 | 7 | 8 | 8 | 7 | 14 | 15 | 16 |
| CWIP ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 6 |
| Investmentsⓘ | 72 | 92 | 96 | 101 | 100 | 98 | 107 | 117 | 110 | 121 |
| Inventories | 2 | 3 | 3 | 3 | 5 | 6 | 4 | 5 | 2 | 4 |
| Trade Receivables | 13 | 16 | 15 | 21 | 23 | 17 | 23 | 41 | 53 | 62 |
| Cash Equivalents | 5 | 3 | 2 | 4 | 4 | 3 | 6 | 2 | 18 | 19 |
| Others Assetsⓘ | 25 | 3 | 4 | 9 | 32 | 42 | 49 | 50 | 51 | 58 |
| Total Assets ⓘ | 126 | 125 | 128 | 144 | 171 | 173 | 195 | 231 | 250 | 285 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | -8 | 18 | 1 | -1 | 7 | 7 | 6 | 5 | 6 | -1 |
| PBT ⓘ | -1 | -2 | 0 | 7 | 20 | 5 | 8 | 14 | 19 | 23 |
| Adjustment ⓘ | 2 | 1 | 1 | -1 | -3 | -4 | 0 | 0 | 2 | 3 |
| Changes in Working Capital ⓘ | -9 | 20 | 0 | -7 | -5 | 9 | 0 | -6 | -11 | -21 |
| Tax Paid ⓘ | 0 | 0 | 0 | 0 | -4 | -2 | -1 | -3 | -4 | -7 |
| Cash Flow From Investing Activity ⓘ | -31 | -20 | -1 | -2 | -22 | -10 | -5 | -16 | 6 | -10 |
| Capex | 0 | 0 | -1 | -1 | -2 | -1 | 0 | -8 | -4 | -7 |
| Net Investments | 11 | -20 | 0 | -2 | 2 | 0 | 0 | -7 | 7 | -3 |
| Others ⓘ | -42 | -1 | 0 | 1 | -22 | -9 | -5 | -1 | 3 | -1 |
| Cash Flow From Financing Activityⓘ | 0 | 0 | 0 | 6 | 15 | 1 | 2 | 8 | 3 | 11 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 4 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | -1 | -2 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | -1 | -2 | 0 | 0 | 0 | 0 |
| Others ⓘ | 0 | 0 | 0 | 3 | 15 | 3 | 2 | 8 | 4 | 9 |
| Net Cash Flow ⓘ | -39 | -2 | 0 | 2 | 0 | -1 | 3 | -3 | 15 | 0 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | -0.16 | -1.75 | -0.03 | 5.06 | 10.65 | 2.97 | 3.93 | 6.23 | 8.59 | 8.51 |
| ROCE (%) | -0.66 | -2.04 | -0.26 | 6.01 | 13.79 | 3.79 | 4.91 | 7.83 | 9.9 | 10.75 |
| Asset Turnover Ratio | 0.15 | 0.17 | 0.22 | 0.37 | 0.61 | 0.35 | 0.38 | 0.49 | 0.49 | 0.49 |
| PAT to CFO Conversion(x) | N/A | N/A | N/A | -0.17 | 0.47 | 1.75 | 1 | 0.45 | 0.38 | -0.06 | Working Capital Days |
| Receivable Days | 204 | 252 | 201 | 127 | 83 | 121 | 104 | 112 | 146 | 159 |
| Inventory Days | 48 | 43 | 34 | 19 | 14 | 31 | 24 | 15 | 11 | 8 |
| Payable Days | 183 | 125 | 150 | 94 | 45 | 68 | 100 | 125 | 177 | 152 |
Kilitch Drugs is a pharmaceutical company, its services range from manufacturing to marketing a host of formulations in all dosage forms i.e. solid, liquid and parenteral forms. With nearly two decades of creating safe pharmaceutical solutions and the ultimate purpose of making the world a healthier place.
Kilitch is one of the largest manufacturers of antibacterial parenteral formulations. It is also one of the largest producers of sterile liquid formulations in small volumes in India. Kilitch also boasts of 25 years of quality contract manufacturing service to reputed national and multinational pharmaceutical companies. its sound knowledge about the industry has resulted in the growth of the organizations along with them as a leading contract manufacturing company in the country.
Keeping pace with the increasing demand of its clients for contract manufacturing, Kilitch has added 2 dedicated blocks and is in the process of adding another 3 dedicated fully USFDA / UKMHRA compliant manufacturing facility in Paonta Sahib (North India). All its plants are approved by the local as well as World Health Organization (WHO) for GMP standards. Kilitch has 3 manufacturing facilities spread across India.
Kilitch has over 25 years of experience in product development and manufacturing. It offers a wide spectrum of contract services, providing reliable supply, scientific expertise and bottom line results to meet the development, clinical and commercial outsourcing needs. Kilitch has been engaged in successful tie-ups with over 20 leading pharmaceutical companies -- Ranbaxy Laboratories Limited, Sandoz India Limited, Zydus Cadila, Nicholas Piramal India Limited, USV Limited, Merck Limited to name a few.
In 2010 the company listed its Equity Shares at NSE.
DCGI Approval-- The company has received the DCGI approvals for Ceftriaxone+Tazobactam, Ceftriaxone+Salbactam,Cefipime +Tazobactam and awaiting for approval for the following products, Rabeprazole, Ceftazidime+Tazobactam, Cefoperazone+Tazobactam
Product range of the company includes- Carbapenems, Cephalosporins, Beta - Lactam Antibiotics, Steroids & Hormones, Gastrology, Gastrology, NSAIDs, Anti Malarials
Kilitch has signed an agreement with a US-based pharmaceutical company for manufacturing of its generic molecules for the period of 2 year which started in mid 2008 and would like to expand their business thereon.
Clientele: Sandoz, Ranbaxy, Emcure, Nicholas, Ajanta pharma, Zuventas, Zydus Cadilla, USV, Flamingo Pharma and many others.
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
FREE Become a savvy and confident
stock investor.
Hurry, limited to the first 10 users today!
Download APP
